Clinical Trial · NCT01598558

Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT

Overview

Rituximab is an antibody targeted against the CD20 antigen found primarily on B-cells. Therefore, an imaging agent targeting CD20 expression may provide a more accurate evaluation of extent of disease and response to therapy than the current standard of care, F-18 FDG PET/CT. The main purpose of the study is to investigate a new PET/CT imaging probe for detection and follow up of lymphoma. Following are the 3 aims of the study: a) Phase I testing in lymphoma patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability, pharmacokinetics and radiation dosimetry; b) comparison of Cu-64 Rituxan and F-18 FDG PET/CT in lymphoma patients; c) evaluation of changes in uptake of Cu-64 Rituxan in response to rituximab-based treatment in CD20-positive B-cell NHL

Sponsor

Stanford University

Phase

N/A

Contacts

Sanjiv Gambhir, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01598558

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

rituximab

Isotope(s):

Target(s):

cd20

Ligand Class: Antibodies

Chelator: DOTA

Eligibility

Inclusion

Patients must have a diagnosis of CD20-positive B-cell NHL and a staging 18F FDG PET/CT prior to the 64Cu-DOTA-Rituximab PET/CT
Patients must be scheduled for rituximab-based therapy

Exclusion

Patients participating in other research protocols will be excluded from this study
Patients who cannot complete a PET/CT scan
Pregnant women